- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06674863
Räätälöity selviytymishoitosuunnitelma, jolla parannetaan selviytymishoidon ymmärtämistä ja saatavuutta mustilla tai afroamerikkalaispotilailla, joilla on paikallinen tai oligometastaattinen eturauhassyöpä
Terveyslukutaidon käsitteleminen räätälöidyn selviytymissuunnitelman avulla, jotta heikosti hoidettujen afroamerikkalaisten eturauhassyöpäpotilaiden saatavuutta voidaan parantaa
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVES:
I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.
II. To quantify the potential benefit of tailoring the care plan and the educational supplement.
III. Compare providers' assessment of patients':
IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.
GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Kerry L. Kilbridge, MD, MSc
- Puhelinnumero: 617-632-2429
- Sähköposti: Kerry_Kilbridge@DFCI.HARVARD.EDU
Opiskelupaikat
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Rekrytointi
- Emory University Hospital/Winship Cancer Institute
-
Ottaa yhteyttä:
- Sierra Williams
- Puhelinnumero: 404-778-4898
- Sähköposti: sierra.williams@emory.edu
-
Päätutkija:
- Viraj Master, MD, PhD, FACS
-
Atlanta, Georgia, Yhdysvallat, 30303
- Rekrytointi
- Grady Memorial Hospital
-
Ottaa yhteyttä:
- Sierra Williams
- Puhelinnumero: 404-778-4729
- Sähköposti: sierra.williams@emory.edu
-
Päätutkija:
- Viraj Master, MD, PhD, FACS
-
Atlanta, Georgia, Yhdysvallat, 30329
- Rekrytointi
- Atlanta VA Medical Center
-
Ottaa yhteyttä:
- Sierra Williams
- Puhelinnumero: 404-778-4729
- Sähköposti: sierra.williams@emory.edu
-
Päätutkija:
- Mohammad Hajiha, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
- Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included
Exclusion Criteria:
- Dementia or cognitive impairment per provider clinical assessment
- Unable to give informed consent in the judgement of the patient's oncology provider
- Recurrent prostate cancer after primary treatment
- Less than 18 years of age at the time of informed consent
- Diagnosis of active second malignancy requiring treatment
- Individuals who are not able to clearly understand English since the outcome measures require understanding of English
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Group I (standard SCP, tailored SCP)
Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes. |
Ancillary studies Receive a low literacy educational supplement
Muut nimet:
Undergo a structured interview Receive standard SCP
Muut nimet:
Receive a tailored SCP
Muut nimet:
|
|
Active Comparator: Group II (standard SCP)
Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes. |
Ancillary studies Undergo a structured interview Receive standard SCP
Muut nimet:
Receive a tailored SCP
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
Aikaikkuna: At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
|
Comprehension of treatment side effects and late effects
Aikaikkuna: At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Access to survivorship care for late and long-term side effects
Aikaikkuna: At baseline and up to 3 month phone call
|
Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Decision regret
Aikaikkuna: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Change in decisional conflict
Aikaikkuna: At baseline and up to 3 month phone call
|
The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement). |
At baseline and up to 3 month phone call
|
|
Preparedness for survivorship
Aikaikkuna: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Patient self-efficacy
Aikaikkuna: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Viraj Master, MD, PhD, FACS, Emory University Hospital/Winship Cancer Institute
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Sukuelinten sairaudet
- Sukuelinten kasvaimet, mies
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Sukuelinten sairaudet, mies
- Eturauhasen sairaudet
- Miesten urogenitaaliset sairaudet
- Eturauhasen kasvaimet
- Terveydenhuollon laatu, saatavuus ja arviointi
- Tutkintatekniikat
- Epidemiologiset menetelmät
- Terapeuttiset lääkkeet
- Tiedonkeruu
- Terveydenhuollon arviointimekanismit
- Terveydenhuollon laatu
- Kansanterveys
- Ympäristö ja kansanterveys
- Potilashoito
- Terveyspalvelut
- Terveydenhuoltolaitokset työvoima ja palvelut
- Lasten terveyspalvelut
- Yhteisön terveyspalvelut
- Ennaltaehkäisevät terveyspalvelut
- Sosioekonomiset tekijät
- Väestöominaisuudet
- Menetelmät
- Haastattelut aiheena
- Lievittävä hoito
- Varhainen interventio, koulutus
- Koulutusasema
Muut tutkimustunnusnumerot
- STUDY00008365
- P30CA138292 (Yhdysvaltain NIH-apuraha/sopimus)
- STUDY00008365 (Muu tunniste: Emory University Hospital/Winship Cancer Institute)
- NCI-2024-08650 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
- WINSHIP6368-24 (Muu tunniste: Emory University Hospital/Winship Cancer Institute)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .